New long-term clinical data presented by Eisai add to growing evidence that LEQEMBI (lecanemab) may continue to slow disease progression in certain adults with early Alzheimer’s disease when treatment is maintained over several years. …
New long-term data suggest sustained benefit of Eisai therapy in early Alzheimer’s Disease
January 30, 2026 Latest NewsBioPharma
Latest Video
Georgia Forrest
New Stories
-
Another potential turning point for immunotherapy access in Australia
February 1, 2026 - - Latest News -
Better Access Australia’s plan to make care fair, affordable and accountable
February 1, 2026 - - Latest News -
Pfizer calls for Budget shift, citing missed medicines and the impact of lost productivity
February 1, 2026 - - Latest News -
Vertex announces PBS listing of new once-daily treatment for cystic fibrosis
February 1, 2026 - - Latest News -
The 'Dispatched' Podcast - Episode 2, Series 5
January 30, 2026 - - Podcast -
New long-term data suggest sustained benefit of Eisai therapy in early Alzheimer’s Disease
January 30, 2026 - - Latest News -
Amgen announces leadership transition for Australia and New Zealand
January 30, 2026 - - Latest News